Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MEDI7352 for infusion · 1 trial · 1 indication
Adverse events, serious adverse events,
| Arm | Type | Description |
|---|---|---|
| MEDI7352 IV | EXPERIMENTAL | Up to 11 cohorts of subjects are planned to be dosed by IV infusion, with single and multiple ascending doses. |
| IV Placebo | PLACEBO_COMPARATOR | Up to 11 cohorts of subjects are planned to be dosed by IV infusion, with single and multiple ascending doses. |
| MEDI7352 Subcutaneous Injection | EXPERIMENTAL | 1 cohort of subjects is planned to be dosed by subcutaneous injection, one single ascending dose cohort. |
| Subcutaneous Placebo | PLACEBO_COMPARATOR | 1 cohort of subjects is planned to be dosed by subcutaneous injection, one single ascending dose cohort. |
| Name | Type | Description |
|---|---|---|
| MEDI7352 for IV infusion | BIOLOGICAL | MEDI7352 for IV infusion |
| Placebo for IV infusion | BIOLOGICAL | IV Placebo infusion |
| MEDI7352 for Subcutaneous Injection | BIOLOGICAL | MEDI7352 for subcutaneous injection |
| Placebo for Subcutaneous Injection | BIOLOGICAL | Subcutaneous Placebo Injection |
Inclusion Criteria: * Male and female subjects with painful osteoarthritis (OA) of the knee. Female subjects must be postmenopausal or surgically sterile. * Body weight between 50kg and 145kg * Willing and able to comply with the requirements of the protocol Exclusion Criteria: * Current treatmen...
MEDI7352 for infusion is an investigational monoclonal antibody being developed by AstraZeneca PLC (AZN) for the treatment of chronic pain. It is administered via infusion and has been studied in a Phase 1 clinical trial for painful osteoarthritis of the knee.
MEDI7352 is being studied for use in chronic pain, specifically in a Phase 1 trial for painful osteoarthritis of the knee. The trial enrolled 132 participants and was conducted in Germany, Sweden, and the United Kingdom.
MEDI7352 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. The drug is an investigational monoclonal antibody for chronic pain.
MEDI7352 is in Phase 1 clinical development. It has completed one Phase 1 trial, which was a randomized, double-blind, placebo-controlled study in patients with painful osteoarthritis of the knee. The drug is still investigational and not yet approved.
MEDI7352 has one completed clinical trial, identified as NCT02508155, titled 'A Study of MEDI7352 in Painful Osteoarthritis of the Knee.' This Phase 1 study enrolled 132 participants and was conducted in Germany, Sweden, and the United Kingdom.